Impact of rituximab and corticosteroids on late cytopenias post chimeric antigen receptor T-cell therapy

Chimeric antigen receptor T-cell (CAR T-cell) therapy represents a paradigm shift in the treatment of relapsed and/or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity (ICANS) are the most acute serious adverse events associated with CAR T-cell therapy; and cytopenias are the most common adverse event observed post CAR T-cell therapy. Cytopenias of all grades have been observed post CAR T-cell therapy and represent a particular challenge for recipients of these therapies.

Source: Biology of Blood and Marrow Transplantation - July 13, 2022 Category: Hematology Authors: Madiha Iqbal, Radhika Bansal, Farah Yassine, Sangeetha Gandhi, Allison Rosenthal, Muhamad Alhaj Moustafa, Zhuo Li, Emily C Craver, Razan Mohty, Hemant Murthy, Ernesto Ayala, Han Tun, Javier Munoz, Januario Castro, Yi Lin, Mohamed A. Kharfan-Dabaja Source Type: research